No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Fragile X Syndrome (FXS) is a genetic disorder that is the most common inherited cause of intellectual disability and autism. It is caused by a mutation in the FMR1 gene, which leads to an absence of the FMRP protein. As a result, individuals with FXS experience a range of cognitive, behavioral, and physical symptoms.
The Fragile X Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs that are used to treat the symptoms of FXS, such as cognitive impairment, anxiety, and hyperactivity. These drugs are typically prescribed by neurologists and psychiatrists, and may include antipsychotics, antidepressants, and stimulants.
The Fragile X Syndrome Drug market is a growing field, as more research is conducted into the disorder and its treatment. Companies in this market include Shire, Novartis, and Ovid Therapeutics. Show Less Read more
